There are, naturally, concerns over the cost to the NHS (and all other "customers") of DCVax.
Treatments exceeding £30,000 per QALY require strong justification for approval. ... [&] ...Additionally, any drug expected to cost the NHS £20 million or more annually in its first three years triggers a commercial negotiation to manage budget impact.
Some years ago (I think in the 20-teens) there was talk on this board about how Mrs Powers came to leave the finance industry and move into a drug development company involved with a treatment for glioblastoma. It was said at that time that it was because her much-loved father, a retired US Marine Corps Master Sergeant who had seen active service in WW2 , had died of a brain tumour and consequently she wanted to help find a cure. This was alluded to in a post by Crashoverride (#571976) on 28 Feb. 2023 when the matter under discussion was Mrs Power's involvement with Advent. The gist of Crashoverride's post, as I read it, was that Mrs Power's involvement in NWBO was not primarily financial and her involvement in Advent was both to protect NWBO from a possible future "hostile" owner of the means of production and, possibly, for Advent to be be her future nest egg.
The corollary of this thesis would be that the cost of DCVax to the customer - be it the NHS or the individual - would not need to follow the Big Pharma model of pricing in which the price of the "new best" drug would be the price of the drug it superseded plus 10% or so, irrespective of the actual cost of production and debt repayment (with the possibility of HUGE profits to the company). Instead, knowing from the very early days that DCVax had already been shown to be active against all sorts of solid tumours, the sheer volume of its ultimate production (if its agnostic nature was accepted) would allow a much lower price for the treatment.
I believe that NWBO knows that it could play very hard ball in negotiations with NICE over the price of DCVax, but I also believe that it will not insist on an over-the-top price just because it could justify it financially.
Market Data 
Markets 
